Zai Lab (BMV:ZLAB N) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

ZLAB N Panoramica delle azioni

Develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience.

ZLAB N analisi fondamentale
Punteggio fiocco di neve
Valutazione	4/6
Crescita futura	5/6
Prestazioni passate	0/6
Salute finanziaria	4/6
Dividendi	0/6

Premi

Negoziato a 88.5% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 64.54% all'anno

Analisi del rischio

Le azioni sono altamente illiquide

Importanti vendite da parte di insider negli ultimi 3 mesi

Zai Lab Limited Concorrenti

Genomma Lab Internacional. de

BMV:LAB B

Mex$21.2b

BioCryst Pharmaceuticals

NasdaqGS:BCRX

US$1.6b

Suzhou Zelgen BiopharmaceuticalsLtd

SHSE:688266

CN¥15.2b

Nurix Therapeutics

NasdaqGM:NRIX

US$1.5b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Zai Lab
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$273.00
Massimo di 52 settimane	US$512.26
Minimo di 52 settimane	US$270.64
Beta	1.05
1Variazione di 1 mese	0%
Variazione a 3 mesi	n/a
Variazione di 1 anno	n/a
3Variazione a 3 anni	n/a
Variazione a 5 anni	n/a
Variazione dall'IPO	-81.55%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	ZLAB N	MX Biotechs	MX Mercato
7D	0%	0%	0%
1Y	n/a	0%	0%

Ritorno vs Industria: Dati insufficienti per determinare come si è comportato ZLAB N rispetto al settore MX Biotechs.

Rendimento vs Mercato: Dati insufficienti per determinare la performance di ZLAB N rispetto al mercato MX.

Volatilità dei prezzi

Is ZLAB N's price volatile compared to industry and market?
ZLAB N volatility
ZLAB N Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Prezzo delle azioni stabile: ZLAB N non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di ZLAB N nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2013	2,175	Samantha Du	www.zailaboratory.com

Zai Lab Limited Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Zai Lab con la sua capitalizzazione di mercato?
ZLAB N statistiche fondamentali
Capitalizzazione di mercato	Mex$34.57b
Guadagni(TTM)	-Mex$6.49b
Ricavi(TTM)	Mex$5.58b

6.2x

Rapporto P/S

-5.3x

Rapporto P/E

ZLAB N è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
ZLAB N Conto economico (TTM)
Ricavi	US$291.07m
Costo del fatturato	US$380.14m
Profitto lordo	-US$89.07m
Altre spese	US$249.88m
Guadagni	-US$338.95m

Ultimi guadagni dichiarati

Mar 31, 2024

Prossima data di guadagno

Aug 06, 2024

Utile per azione (EPS)	-3.42
Margine lordo	-30.60%
Margine di profitto netto	-116.45%
Rapporto debito/patrimonio netto	6.3%

Come si è comportato ZLAB N nel lungo periodo?

Vedi performance storica e confronto

ZLAB N Panoramica delle azioni

Premi

Analisi del rischio

Zai Lab Limited Concorrenti

BMV:LAB B

Mex$21.2b

NasdaqGS:BCRX

US$1.6b

SHSE:688266

CN¥15.2b

NasdaqGM:NRIX

US$1.5b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Zai Lab Limited to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024

Zai Lab and argenx Announces Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

Zai Lab Limited to Report Q2, 2024 Results on Aug 06, 2024

Zai Lab Limited Announces Executive Changes, Effective June 30, 2024

Zai Lab Limited Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis

Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

Recent updates

Zai Lab Limited to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024

Zai Lab and argenx Announces Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

Zai Lab Limited to Report Q2, 2024 Results on Aug 06, 2024

Zai Lab Limited Announces Executive Changes, Effective June 30, 2024

Zai Lab Limited Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis

Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

Zai Lab Limited Announces Approval of AUGTYRO (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA

First quarter 2024 earnings released: US$0.55 loss per share (vs US$0.51 loss in 1Q 2023)

Forecast to breakeven in 2026

Zai Lab Limited to Report Q1, 2024 Results on May 08, 2024

Zai Lab Limited, Annual General Meeting, Jun 18, 2024

Zai Lab Partner Novocure Announces Metis Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating A Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

Zai Lab Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

Zai Lab Limited to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors

Zai Lab Limited to Report Fiscal Year 2023 Results on Feb 27, 2024

Zai Lab Announces the New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC

Zai Lab Limited Announces the First Listing of VYVGART(R) (efgartigimod alfa injection) and Other Updates in China's National Reimbursement Drug List

Zai Lab Limited to Report Q3, 2023 Results on Nov 07, 2023

Zai Lab Limited Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with Ntrk-Positive Tki-Pretreated Advanced Solid Tumors in China

Zai Lab Limited to Report Q2, 2023 Results on Aug 07, 2023

Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod Alfa Injection (Subcutaneous Injection) for Patients with Generalized Myasthenia Gravis

Zai Lab Limited Announces Chief Financial Officer Changes, Effective July 7, 2023

Zai Lab Limited and argenx Announce Approval of VYVGART (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

Zai Lab and Novocure Announces Lunar Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Zai Lab Limited to Highlight New Data from its Oncology Pipeline at 2023 ASCO Annual Meeting

Zai Lab Limited Announces China’s National Medical Products Administration Grants Priority Review to Repotrectinib

First quarter 2023 earnings released: US$0.51 loss per share (vs US$0.86 loss in 1Q 2022)

Zai Lab Limited to Report Fiscal Year 2022 Results on Mar 01, 2023

Zai Lab Limited Announces New Drug Application for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s National Medical Products Administration

Zai Lab Limited Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China’s National Reimbursement Drug List

Zai Lab Limited Appoints Michel Vounatsos to the Board of Directors

Zai Lab Limited and Novocure Announce Pivotal Lunar Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

Zai Lab Limited Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development

Independent Director recently sold Mex$5.5m worth of stock

Zai Lab Limited Presents Interim Overall Survival Data for ZEJULA® (niraparib) from the NORA Phase 3 Study at the ESMO Virtual Plenary

Independent Director recently sold Mex$5.5m worth of stock

Third quarter 2022 earnings released: US$1.68 loss per share (vs US$1.01 loss in 3Q 2021)

Zai Lab Limited Announces the Appointment of Peter Huang as Chief Scientific Officer

Zai Lab Limited to Report Q3, 2022 Results on Nov 09, 2022

Zai Lab to Present Analysis of the Impact of Timing for ZEJULA® (niraparib) Maintenance Treatment in Newly Diagnosed Advanced Ovarian Cancer at the 2022 International Gynecologic Cancer Society Meeting

Second quarter 2022 earnings released: US$1.44 loss per share (vs US$1.76 loss in 2Q 2021)

Zai Lab Limited Appoints Joshua Smiley as Chief Operating Officer

Zai Lab Limited to Report Q2, 2022 Results on Aug 09, 2022

China’s National Medical Products Administration Accepts Biologics License Application of Zai Lab Limited

Zai Lab Limited Announces Breakthrough Therapy Designations Granted for Repotrectinib in China

Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer

First quarter 2022 earnings released: US$0.86 loss per share (vs US$2.64 loss in 1Q 2021)

Zai Lab Limited, Annual General Meeting, Jun 22, 2022

Zai Lab Limited to Report Q1, 2022 Results on May 10, 2022

No longer forecast to breakeven

Zai Lab Limited Announces Resignation of Tao Fu, Chief Strategy Officer

No longer forecast to breakeven

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Zai Lab Limited to Report Fiscal Year 2021 Results on Mar 02, 2022

Zai Lab Limited to Report Fiscal Year 2021 Results on Mar 01, 2022

Forecast to breakeven in 2024

Zai Lab Limited Announces Treatment of First Patient in Greater China in PANOVA-3 Phase 3 Pivotal Trial of Tumor Treating Fields in Pancreatic Cancer

Zai Lab Announces NDA Acceptance of Margetuximab for Patients with Pretreated Metastatic HER2-Positive Breast Cancer in China by the NMPA